Sakar Healthcare Posts 38% Revenue Growth in Q1 FY27; Profit After Tax Rises 120%, Driven by Oncology Focus

Sakar Healthcare Posts 38% Revenue Growth in Q1 FY27; Profit After Tax Rises 120%, Driven by Oncology Focus​

Ahmedabad, July 24, 2026: Sakar Healthcare Ltd., a manufacturer of oncology orals and injections with EU GMP approval, announced its unaudited financial results for the first quarter of the fiscal year (Q1 FY27) ending June 30, 2026. The company reported significant gains in revenue and profitability, underpinned by strategic growth across its oncology platform and global market engagements.

Consolidated Financial Performance​

Sakar Healthcare demonstrated robust performance in Q1 FY27. Revenue from operations grew by 38% year-over-year (YoY), while Profit After Tax saw a sharp increase of 120%. The company's EBITDA margin stood at 29%.

The consolidated unaudited financial results are as follows:

Business and Operational Highlights for Q1 FY27​

The company reported several milestones across its R&D and regulatory initiatives:

• Oncology Engagements: More than 65 oncology product contracts were executed, with over 50 commercial discussions currently ongoing.
• Dossier Submissions: A total of 261 dossiers were shared globally; 178 have been submitted, and 16 dossiers received Marketing Authorisations. For the 32 developed oncology products, dossiers were shared for 21, resulting in 16 dossier approvals.
• Marketing Authorisation (MA) Filings: The company completed 26 EU MA filings, including 15 proprietary submissions. An additional 6 MAs were procured through partners located in Bulgaria and Bosnia. Remaining filings cover the Czech Republic, Croatia, and Portugal.
• Site Variations: 33 site variations covering 18 cytotoxic molecules across the EU and the UK were submitted, with seven approvals secured.
• API Development: 21 APIs were developed in-house, including 16 APIs with Written Confirmation, 8 Commercialised products, two API’s with CEP approval, and five CEP applications are currently processing.
• Technology Transfer Projects: Three companies (Accord-Intas, Torrent, Emcure, Glenmark, and Zydus) are involved in technology transfer projects for oncology products. Seven of these projects have received site variation approvals: two in the UK and five in the EU.

Financial Performance Summary​

Revenue from operations for Q1 FY27 reached ₹ 7,297 lakhs, reflecting a 38% YoY growth, supported by new market authorizations and strong demand across various countries. EBITDA increased to ₹ 2,125 lakhs, marking a 67% rise YoY, while the EBITDA margin stood at 29%. The company achieved a significant improvement in profitability, with the PAT margin expanding to 14% YoY, indicating improved efficiencies and disciplined cost management alongside operating leverage.

Management Commentary​

Mr. Sanjay Shah, Managing Director, commented on the results, stating that Q1 FY27 represented steady progress supported by healthy year-on-year growth. He noted that the company is on a strong growth trajectory in revenue and profitability, with the oncology business being a key pillar of the strategy. During the quarter, commercial engagements were expanded, export momentum strengthened, and progress was advanced across dossier submissions, Marketing Authorisations, site variation approvals, and technology transfer projects.

Looking ahead, Mr. Shah expressed confidence that converting regulatory approvals into commercial launches and supplies, coupled with growing export opportunities and the gradual ramp-up of oncology volumes, will enhance capacity utilization and operating leverage. The long-term outlook is described as promising, underpinned by the scalability of the oncology platform and the progressive commercialization of the product portfolio.

About Sakar Healthcare Limited​

Established in 2004 and based in Ahmedabad, Gujarat, Sakar Healthcare Limited operates as a publicly listed pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations. The company operates EU-GMP and WHO-GMP certified facilities capable of manufacturing oral solids, injectables, oral liquids, and high potent oncology products.

Sakar’s oncology division, located in Bavla, is a research driven, API integrated facility focused on developing and commercializing complex cytotoxic formulations and APIs. With an extensive global footprint across more than 60 countries, Sakar serves as a trusted partner to multinational pharmaceutical companies through CDMO, CRAMS, and technology transfer collaborations, committed to delivering world-class healthcare solutions.

SAKAR Stock Price Movement​

Sakar Healthcare Limited shares slipped today, finishing in the red after shedding 2.85% to settle at ₹802.2. The stock saw a total traded volume of 547,254 shares during the session.